HIGHBuilt-inPipeline
tovecimig (lead product candidate)
“10-K Item 1: 'Our lead product candidate, tovecimig (formerly known as CTX-009), is a bispecific antibody targeting Delta-like ligand 4'”
CMPX · Concentration risk · 10-K extracted
Compass Therapeutics (CMPX) concentration risks
Updated
The most significant concentration Compass Therapeutics discloses is tovecimig (lead product candidate), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Compass Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCounterparty
ABL Bio (tovecimig licensor)
“10-K Item 1: 'We have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc. (“ABL Bio”), a South Korea-based clinical-stage company focused on developing antibody therapeutics.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Compass Therapeutics' concentration centers on its lead and apparently sole disclosed product candidate, tovecimig (formerly CTX-009), a bispecific antibody targeting Delta-like ligand 4, a high, structural concentration typical of a clinical-stage company with a narrow pipeline. That concentration is paired with a licensing dependency: Compass holds exclusive global rights to tovecimig outside South Korea under a license from ABL Bio, also disclosed at a high level. The two exposures reinforce one another rather than diversify risk — nearly all of the company's near-term value depends on a single molecule, and the rights to develop and commercialize that molecule outside South Korea flow from a single external licensor. A clinical setback for tovecimig would have an outsized effect given the absence of a broader disclosed pipeline, and any disruption to the ABL Bio relationship would threaten the company's rights to its most important asset. Both are well disclosed and characteristic of an early-stage biotech built around one licensed compound.
For the engine’s reasoning on CMPX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| CMPX● | Compass Therapeutics, Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.